A synthetic compound, 1,5‐bis(2‐methoxyphenyl)penta‐ 1,4‐dien‐3‐one (B63), induces apoptosis and activates endoplasmic reticulum stress in non‐small cell lung cancer cells
A synthetic compound, 1,5‐bis(2‐methoxyphenyl)penta‐ 1,4‐dien‐3‐one (B63), induces apoptosis and activates endoplasmic reticulum stress in non‐small cell lung cancer cells
复制标题
DOI:
10.1002/ijc.27406
复制
发表时间:
2012-09
影响因子:
6.4
通讯作者:
Jian Xiao;Yi Wang;Jing Peng;Lu Guo;Jie Hu;M. Cao;Xie Zhang;Hangyu Zhang;Zhouguang Wang
中科院分区:
文献类型:
--
作者:
Jian Xiao;Yi Wang;Jing Peng;Lu Guo;Jie Hu;M. Cao;Xie Zhang;Hangyu Zhang;Zhouguang Wang
Endoplasmic reticulum (ER) stress‐induced cancer cell apoptosis has become a novel signaling target for the development of therapeutic drugs for cancer treatment. Curcumin, a dietary phytochemical, exhibits growth‐suppressive activity against cancer cells via multitarget mechanisms. However, the low stability and poor pharmacokinetics significantly limit its clinical applications. Thus, we designed and synthesized a novel monocarbonyl analog of curcumin, 1,5‐bis(2‐methoxyphenyl) penta‐1,4‐dien‐3‐one (B63). This compound exhibited a higher chemical stability in cultural medium and a better intracellular profile than curcumin. Treatment with B63 potently induced apoptosis of human non‐small cell lung cancer (NSCLC) cells in a dose‐responsive manner, while exhibiting no cytotoxicity in normal lung fibroblast cells. Its antitumor effect was associated with the ER stress‐mediated apoptotic pathway and, ultimately, the activation of the caspase cascades. However, curcumin at the same concentrations did not cause ER stress in H460 cells. Further, C/EBP homologous protein knockdown by siRNA attenuated B63‐induced cell apoptosis, indicating that the apoptotic pathway is ER stress‐dependent. In vivo, the volume and weight of the tumor were reduced significantly by pretreating the H460 tumor cells with B63 before implantation. Taken together, these insights on the novel compound B63, from both chemical and biological perspectives, may provide a novel anticancer candidate for the treatment of NSCLC.